- Case report
- Open access
- Published:
Crohn’s disease, irritable bowel syndrome, and chronic fatigue: the importance of communication and symptom management—a case report
Journal of Medical Case Reports volume 19, Article number: 9 (2025)
Abstract
Background
Crohn’s disease and irritable bowel syndrome may both cause abdominal pain and diarrhea. Irritable bowel syndrome not only is an important differential diagnosis for Crohn’s disease but also occurs in one out of three patients with Crohn’s disease in remission in parallel. If not adequately diagnosed and treated, additional functional symptoms such as fatigue and/or muscle pain may develop, indicating a more severe course.
Case presentation
A 64-year-old Caucasian male with long-standing, widely inactive Crohn’s disease presented with persistent diarrhea, bloating, abdominal pain, general fatigue, unexplained hip pain, and frequent shivering with cold extremities, which had worsened following a gastrointestinal infection and psychological stress. A plausible explanation of his symptoms, based on an understanding of mind–body interactions, the autonomic nervous system, and temperature regulation, combined with symptom relief, was associated with rapid and sustainable improvement. After 2.5 years of follow-up, the patient is almost symptom-free.
Conclusions
This case report exemplifies the interrelation between organic (Crohn’s disease) and functional diseases (irritable bowel syndrome, chronic fatigue syndrome, and somatoform pain). It further demonstrates that these connections may be overlooked in daily practice and that providing a plausible explanation in combination with symptom relief may be important for patients with functional syndromes.
Background
Inflammatory bowel diseases (IBDs) include the subtypes Crohn’s disease (CD) and ulcerative colitis (UC) and are characterized by an overactive immune system destructive to the gastrointestinal tract [1,2,3]. Patients with CD present with various, often unspecific abdominal symptoms, in particular diarrhea, bloating, cramps, abdominal pain, and fatigue. In more severe cases, bloody stools, weight loss, fever, anemia, stenosis, or fistulae may be present [4, 5]. Owing to overlapping symptoms, irritable bowel syndrome (IBS) is an important differential diagnosis for CD. IBS is considered a common functional disorder of gut–brain interaction, with symptoms mainly triggered by diet, stress, medications, and gastrointestinal infections [6,7,8,9,10,11]. It is now established that not only IBS but also IBD is associated with dysregulated gut–brain and microbiota–gut–brain axes, providing the physiological link between the central nervous system (CNS) and the gastrointestinal tract [12,13,14,15,16]. Accurate diagnosis, primarily through ileocolonoscopy and blood tests, is essential to distinguish between these two conditions and other possible disorders, ensuring appropriate management. The treatment of CD aims to control the body’s inflammatory response with the help of immunomodulators and corticosteroids. Surgical intervention may be required in case of stenosis or fistulae.
Over the past two decades, a growing body of evidence has shown that patients with CD in remission may experience symptoms of IBS [17,18,19,20,21,22,23,24,25], sometimes making differentiation challenging, as concomitant IBS symptoms can mimic active IBD. Accurate diagnosis through patient-centered dialog is crucial for appropriate medical and behavioral management [18, 26,27,28,29,30]. Studies have shown that the frequency of IBS in CD patients in long-term remission can be as high as 35%, which is three times higher than the global prevalence of IBS symptoms in the general population (11%) [8, 17,18,19,20,21,22,23,24,25], with a considerable impact on their quality of life [19, 20]. With this case report, we aim to highlight this concurrence of CD with IBD and provide an example of initial neglect and ultimately successful treatment.
Case presentation
Current medical history
A 64-year-old Caucasian male presented in February 2022 with persistent diarrhea, bloating accompanied by abdominal pain, frequent headaches, shivering, and cold extremities lasting for 2–3 weeks each month, insomnia, and general fatigue. He had a history of Crohn’s disease (CD) with an ileocecal resection involving 42 cm of the terminal ileum and 10 cm of the cecum immediately following his initial diagnosis in early 1981, Montreal Classification A2, L3, B3 [31]. Biopsies from the terminal ileum and ascending colon revealed transmural inflammation and epithelioid granulomas. Since surgery, CD had widely remained in remission, with occasional episodes of low-grade nonspecific ileitis (1984, 1991, 2006) and low-grade chronic colitis (1986) seen on ileocolonoscopy (Table 1). Inappropriate to CD in remission, the patient suffered from chronic diarrhea, up to four times a day and often imperative, which numerous medical specialists that he consulted considered to be unusual. Annual ESR, CRP, and blood count results were normal. The patient was taking cholestyramine 6 g per day, loperamide hydrochloride 2 mg per day, probiotic bacterial cultures (1.1 × 1010 CFU per capsule) two capsules once daily (self-medication), cyanocobalamin 1000 µg IM every 6 months, and ramipril 5 mg once daily. He had no history of smoking or alcohol consumption and reported a paternal family history of asthma and neurodermatitis. There was no family history of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS).
Expanded medical history
From early childhood, he was exposed to stressful life events, including being placed in an infant home from age 0 to 6 months, experiencing physical and emotional abuse in a children’s sanatorium at age 9, and frequent changes of caregivers (various nurses, grandparents, an aunt, parents, and a nanny). Until the age of 3, he frequently refused to eat and later suffered from asthma, food-related skin rashes, and frequent infections, which were treated with antibiotics and resulted in frequent absences from school. At age 9, he underwent tonsillectomy and was sent to a sanatorium 900 km away.
When the patient was 21 (1979), during his first year of studies at university, an elevated ESR was incidentally discovered. Persistent diarrhea began during his pre-graduate examinations in 1980, accompanied by weight loss (from 78 to 62 kg within 4 months) and abdominal pain after food intake (Table 1). In early 1981, the patient canceled his current year of studying abroad owing to persistent diarrhea, increased and persistent pain in the right lower abdomen, continuous weight loss, and general fatigue. When fever occurred, exploratory open abdominal surgery was performed in February 1981 to drain a right-sided iliopsoas abscess. Two weeks later, a conglomerate of caked intestinal loops was removed during an open ileocecal resection (ICR). The patient was discharged on a light vegetarian diet and sulfasalazine 2 g once daily, with a weight of 60 kg. The main symptom remained diarrhea, with up to six episodes out of up to eight bowel movements (BM) per day. Cholestyramine instantly reduced the frequency of diarrhea to 0–2 per day (1–3 BM/day). From 1985 (age 27), the patient’s condition stabilized. He spent 2 months in the Philippines for extensive martial arts training, enjoying very good health with no CD-related symptoms. The patient followed a vegetarian diet but avoided milk, eggs, hard cheese, wholegrain products, raw vegetables, citrus fruits, and fruit juices to prevent bowel problems. In 1995, he underwent laparoscopic cholecystectomy for cholecystolithiasis, a common complication in CD patients (Table 1).
During years of being bullied by a superior (2008–2017) while holding an attractive position at a European Union research institution since 2006, the patient’s blood pressure increased from 130/85 mmHg in 2008 to 160/95 mmHg in 2017, and his weight rose from 74 to 82 kg. Additional symptoms manifested in 2017, primarily painful diarrhea two to three times daily, frequent flu-like symptoms, fatigue, urinary urgency, and cold extremities (Table 1). Flu-like symptoms and shivering mainly occurred after fitness exercise, long-distance flights, or exposure to cold air. They occurred without fever, did not involve the upper respiratory tract, and lasted for 2–3 weeks approximately six times a year. The patient had to take extended medical leave in 2017, ultimately leading to early retirement for health reasons in 2020. He no longer felt sociable and avoided making appointments. He consulted gastroenterologists, internists, and psychosomatic specialists, who explained, that the frequent “colds” were most likely due to a weakened immune system caused by stress. Following a severe gastrointestinal infection of unknown origin in 2019, episodes of diarrhea, bloating with abdominal pain, and flu-like symptoms intensified. These episodes now occurred on a monthly basis especially after exposure to cool air or moderate physical exercise, each lasting 2–3 weeks. They were accompanied by general fatigue, headache, brain fog, dizziness, poor memory, exceptional tiredness, and abdominal pain, which was most pronounced before BMs. Additionally, bloating, sometimes accompanied by diarrhea, tiredness, and drowsiness, would occur within an hour of commencing physical exercise or intense intellectual work, forcing the patient to suspend these activities. Conversely, a short walk or light exercise alleviated headache, fatigue, and tiredness. Insomnia and the inability to wind down resulted in nonrestorative sleep and daytime tiredness.
The patient also reported episodic unilateral hip pain starting in 2020, which became bilateral by 2022, sometimes so severe that he was unable to walk more than 100–200 m. However, MRI and X-ray scans only revealed low-grade osteoarthritis, which did not explain the severe intermittent pain. The patient’s self-trials with probiotic bacteria, aimed at alleviating a suspected leaky gut syndrome, proved unsuccessful. Colonoscopy and histology results in August 2019 showed no inflammation in the neoterminal ileum and colon, suggesting that CD was in remission. This was supported by normal ESR, CRP, and complete blood count results.
Physical examination and psychological evaluation
The patient presented in good general condition with a normal body mass index (BMI) of 27 (height 1.76 m, weight 85 kg). He had two surgical scars on his abdomen. Bowel sounds were hyperactive, indicating increased peristalsis, and palpation of the abdomen was normal without tenderness. Examination of the chest, joints, spine, muscles, thyroid, and neurological status revealed no relevant pathological findings. His pulse rate was regular at 58 bpm, and his blood pressure was 150/90 mmHg. The patient was clear in his thoughts, emotionally responsive, and exhibited a normal drive with a tendency toward perfectionism.
Diagnostic interpretation
Our patient presented with a Crohn’s Disease Activity Index (CDAI) score [32] of 183 points (based on weight 85 kg, hematocrit 45%), slightly above the threshold of 150 points, indicating only mild and not necessarily CD-specific activity. The elevated CDAI score was attributable to persistent diarrhea and abdominal pain associated with bloating. Nonspecific, low-grade colitis and ileitis had been detected twice between 1984 and 2006 during regular ileocolonoscopies and histopathological examination of biopsies but did not explain the bowel symptoms that worsened after exposure to cold air, physical exertion, or certain dietary products. Chologenic diarrhea was likely present in the years following ileocecal resection, though not diagnosed specifically, as the patient promptly responded to cholestyramine. Therefore, alternative causes other than CD were considered to explain the patient’s ongoing diarrhea over the past four decades and the additional symptoms experienced since 2017 (Table 2). Food allergies, fructose or lactose intolerance, small intestine bacterial overgrowth, and gluten intolerance were addressed and excluded through detailed history taking or blood tests (negative transglutaminase antibodies). We considered the intermittent pain related to defecation as atypical for CD and more typical for irritable bowel syndrome with diarrhea (IBS-D) [17].
Hallmarks of diarrhea-predominant irritable bowel syndrome (IBS-D), a type of IBS likely present in our patient, include otherwise unexplained persistent diarrhea, bloating, and abdominal pain occurring at least once a week, according to the Rome IV diagnostic criteria [8, 33]. Factors involved in this disorder of the gut–brain axis include increased intestinal permeability, intestinal sensitivity, increased gut motility, changes in gut microbiota composition, visceral hypersensitivity, stress, and anxiety [6, 10, 15].
The natural course of symptoms and risk factors contributing to IBS can begin as early as infancy [8] (Table 1). Early adverse life events, such as those experienced by our patient, can trigger the development of somatic complaints later in life. Risk factors associated with IBS include loss and separation during childhood [34, 35], parental deprivation [35], or rejection [36], emotional [37, 38] and physical abuse [36,37,38,39], punishment [36, 37], conflicted or dependent maternal relationships [34], suppressed feelings of anger and resentment [37], and childhood anxiety [36]. Conversely, studies have shown that parental emotional warmth can be protective against IBS [36]. Frequent infections and antibiotic use in infancy are associated with an increased risk of IBD, while breastfeeding has been shown to be protective against IBD [40].
In adults, stress-induced alterations in neuroendocrine–immune pathways affect the microbiota–gut–brain (MGB) axis, modulated by the vagus nerve, which can lead to a flare-up of IBS symptoms [6, 7, 10, 15, 41]. Stressful life events are known to potentially exacerbate IBD flare-ups by transmitting stress signals from the brain via the enteric nervous system (ENS), triggering inflammatory responses in the gut [42, 43]. Therefore, both IBD and IBS treatment should include the management of stress and stress-related responses [16]. Given our patient’s personal and medical history, and that the symptoms experienced while CD had largely been in remission and without stenosis, we assume that adverse early life events and chronic stress throughout childhood, adolescence, and professional life likely contributed to the development and eventual exacerbation of IBS-D flares.
Increased urinary frequency and urinary urgency, including nocturnal urination, as noted in our patient, have been shown to be associated with IBS and primarily IBS-D, suggesting shared pathophysiology and visceral interactions between the two closely located organs via common sensory pathways [44]. Dysfunction in the autonomic nervous system, that is, an imbalance between the sympathetic and parasympathetic nervous systems, can lead to an overactive bladder [45]. Urinary tract infection, neurological causes, and benign prostate hyperplasia were excluded. Every 2–3 weeks, after physical exertion or exposure to low temperatures, our patient experienced flu-like symptoms and shivering accompanied by diarrhea and cold extremities (Tables 1, 2). Cold extremities can also be related to increased sympathetic nerve activity, as it plays a key role in both circadian temperature regulation and stress response, resulting in peripheral vasoconstriction and consequently reduced heat loss and an increase in the body’s core temperature [46,47,48].
Following a severe gastrointestinal infection in 2019, the patient experienced additional symptoms including headache, brain fog, dizziness, failing memory, and exceptional fatigue after only light physical activities. These symptoms are reminiscent of a condition termed post-exertional malaise (PEM), a characteristic feature of chronic fatigue syndrome (CFS). Indeed, CFS has been shown to occur more frequently in patients with IBS following intestinal infections [49,50,51,52,53]. Strong mental or physical exertion, or time pressure, exacerbated these neurological and cognitive deficits and caused bloating with abdominal pain within about an hour. Conversely, some relief was observed after prolonged periods of relaxation, often overnight [41, 42]. We assumed that the patient approached these activities with high tension and self-expectations, which could have triggered the mentioned vegetative symptoms. Arthralgia/myalgia manifested in the patient in 2020 and can be interpreted as a further somatoform symptom, belonging to the CFS–fibromyalgia complex. The pain-related functional limitations significantly impaired his ability to participate in daily life. Nonrestorative sleep, tinnitus, urinary urgency, and impaired thermoregulation complete a pattern strongly suggestive of autonomic nervous system dysregulation associated with existing IBS-D (Table 2). Our patient observed symptom flare-ups when swimming in cold water or being exposed to cold air. While experiencing almost continuous flare-ups in winter, symptoms were less intense and occurred less frequently in summer. We interpreted this pattern as consistent with our hypothesis. Cool ambient temperatures would activate the sympathetic tone and trigger bodily stress reactions mediated by the autonomous nervous system in this sensitive individual [54]. A prevalence of thermal hypersensitivity, an altered sensation in response to thermal stimuli, along with elevated cortisol levels, has also been found in IBS-D patients [55, 56]. In another study, IBS patients showed significant symptoms after cold water intake [57]. The severity of IBS symptoms and both visceral and thermal hypersensitivity have been shown to be positively correlated [56].
The severe intestinal infection in 2019 exacerbated the patient’s IBS-D symptoms and triggered new debilitating symptoms (neurological, cognitive), as mentioned above. This deterioration can also be understood within the context of our hypothesis if the intestinal infection is regarded as a threatening, stressful event (Tables 1, 2). Studies have shown that up to 35% of IBS-D patients [58] experience a sudden onset or worsening of IBS symptoms following bacterial or viral gastroenteritis, which is one of the strongest risk factors for IBS [8, 52, 58,59,60]. We assume that the infectious gastroenteritis affected the gut–brain axis and increased IBS flare-ups in our patient, classifying this as post-infectious irritable bowel syndrome (PI-IBS) [10, 11, 16, 58, 60,61,62,63,64,65].
In summary, the variety, intensity, and persistence of our patient’s complaints, including numerous nongastrointestinal symptoms and syndromes, were beyond what would be expected in widely inactive Crohn’s disease. On the basis of his medical and personal history since infancy, physical examination, pattern of symptoms, normal laboratory results, absence of any alarm features [8], and a detailed discussion with the informed patient about the course and severity of his symptoms and experiences, we attributed his symptoms to autonomic nervous system dysregulation with disturbance of the gut–brain axis (IBS-D) and CFS.
Therapeutic approach
According to our hypothesis, the interventions were primarily designed to stabilize the autonomic nervous system of the patient. They included establishing a trusting relationship between patient and healthcare provider and, on this basis, explaining to the patient the probable causes of his condition and the origins of his experienced symptoms in detail. Effective symptom management should demonstrate to him that the hypotheses are correct.
For symptom control, loperamide was substituted with a tincture of opium (an oral solution of anhydrous morphine 10 mg/mL extracted from Papaver somniferum L., succus siccus, Dropizol®), which, in our experience, is more effective in reducing intestinal motility. Owing to this advantage, opium tincture has been receiving increasing attention in recent literature for the treatment of chronic functional diarrhea [66,67,68,69]. The extract contains minor amounts of codeine (methyl morphine) and thebaine (dimethyl morphine), as well as the isoquinoline-derived alkaloids papaverine and noscapine [66, 70].
After oral morphine administration, rapid intestinal absorption occurs, with peak plasma levels reached within 30–90 minutes and an average elimination half-life of 1.4–3.4 hours [69]. Morphine is predominantly biotransformed in the liver to two main metabolites: morphine-3-glucuronide (M3G), a µ-opioid receptor antagonist, and the µ-opioid receptor-active morphine-6-glucuronide (M6G), resulting in a relatively low average morphine bioavailability of 35% [69, 71, 72]. The area under the plasma concentration–time curve (AUC) for M6G has been reported to be 10 times larger than that of morphine [73], suggesting that M6G significantly contributes to morphine’s antidiarrheal effect [69]. In comparison, the plasma half-life of orally administered loperamide (9–14 hours) tends to be higher than that of the active morphine metabolite M6G (9–10 hours); however, its bioavailability may be two orders of magnitude lower, at 0.3% compared with 35% for morphine [69]. Both the higher bioavailability of morphine after oral administration and the accumulation of high M6G plasma levels may explain the efficacy of opium tincture over loperamide in the treatment of chronic diarrhea. An additional antidiarrheal effect may be attributed to codeine [69], which is present in minor quantities in opium tincture. Although codeine appears to be six to seven times less potent at the µ-opioid receptor than morphine [74], its potency is still higher than that of the synthetic opiates loperamide and diphenoxylate [66]. Approximately 10% of orally ingested codeine is converted to morphine, primarily in the liver [74], and subsequently to M3G and the µ-opioid receptor-active metabolite M6G.
The manufacturer’s recommended dose of morphine equivalents for adults with chronic diarrhea is 2.5–5.0 mg two to three times a day; however, the dosage should be customized and fine-tuned to optimize results. Morphine equivalent doses of 1.0–10 mg four times a day [66], 1.5–10 mg four times a day [67], and up to 10 mg in a single dose with a maximum total daily dose of 60 mg [69] have been suggested. Our patient started with three drops of opium tincture twice a day (a total daily dose of 3 mg morphine) and gradually increased the dosage until the desired antidiarrheal effect was achieved. The patient was also advised to take one capsule containing 80 mg of Lavandula aspic L. essential oil twice a day (brand name Lasea®), which is known for its relaxing and soothing effects. It has proven efficacious in several randomized controlled trials for treating sleep problems and anxiety [75,76,77]. The patient continued taking 6 g of cholestyramine per day. Ramipril 5 mg once a day was eventually replaced with a combination of 16 mg candesartan cilexetil and 5 mg amlodipine. With a 42-cm ileal resection, our patient was at risk of vitamin B12 malabsorption, which is why we advised him to continue taking methyl cobalamin 500 µg orally disintegrating tablets (ODT) twice a week.
Before presenting to our outpatient clinic, our patient had tried various probiotic preparations containing Lactobacillus spp. and Bifidobacterium spp., but these did not have the desired positive effect on his intestinal complaints.
Since 1981, the patient has followed a trial and error-based vegetarian diet, which was later maintained for ethical reasons as well. Dietary restrictions based on subjective intolerances included, among others, meat, fish, poultry, cow’s milk, lactose-free milk, ice cream, cornflakes, eggs, hard cheeses, deep-fried foods, hot spices (such as pepper and chili), raw vegetables, tomatoes, apples, citrus fruits, pineapple, rhubarb, acidic fruit juices, and soft drinks, as they presumably caused bowel problems.
We suggested a general reduction of stress to stabilize the disturbed autonomic nervous system and gut–brain axis. Suggestions included maintaining regular meal and sleep timing, such as taking dinner early and in moderate quantities to improve the quality and duration of sleep, and avoiding eating immediately before physical exercise. Regarding diet, we recommended a “back to normal” approach. Only raw food, cruciferous vegetables, and wholegrain bread should be avoided, as they may cause bloating and increase stool frequency. We considered regular physical activity to be a key element in managing IBS. However, since our patient tended to exercise with high tension and self-expectation, which triggered vegetative symptoms, we advised him to perform only moderate physical exercise and to monitor his heart rate, keeping it ≤ 130 bpm. The aim of this energy management, known as pacing, is to avoid overloading and excessive stress in everyday life by adhering to the individual stress limits set by the condition. Furthermore, we suggested that he learns relaxation techniques such as yoga or autogenic training and integrates them into his daily lifestyle.
Further course of symptoms and patient´s perspective
Our patient reported an immediate and dramatic improvement in both the frequency and severity of diarrhea after increasing the daily dose of opium tincture from three to six drops twice a day (a total daily dose of 6 mg morphine) while simultaneously discontinuing loperamide. The number of BMs decreased from four to six each day to an average of two per day, and in the two following years, only one or two episodes of diarrhea occurred on 2–3 days per month (Tables 1, 2). Along with the reduction in diarrhea, the intermittent abdominal pain notably improved. General fatigue, along with flu-like symptoms, headache, and brain fog, which had persisted for 2–3 weeks every month before our interventions, was soon reduced to 1 week in a 3-month period and was less severe. The associated insomnia was reduced to about 1 week each month, while hip joint pain, urinary urgency, cold extremities, disturbed temperature regulation, and tinnitus remained unchanged initially. Our patient reported the almost immediate reestablishment of social contacts and, after a few months, the ability to undertake long-distance travel and extensive but heart rate-controlled cycling tours, both of which had previously been impossible for several years. After 2–3 hours on flat terrain (road bike) or about 1 hour on inclines (mountain bike), slight bloating sometimes occurred, which subsided after 1–2 hours, but there was no increase in BMs or diarrhea.
Our patient’s condition improved even further from early 2024 (2 years after the beginning of our multimodal treatment) and has stabilized at a good level since then (reported 2.5 years after the start of treatment) over the following 6 months (Tables 1, 2). He attributed the further improvement to the intake of glutamine (10 g twice a day). In patients with IBS-D, increased intestinal permeability might be due to decreased glutamine synthetase levels [78]. In a randomized, double-blind, placebo-controlled, multicenter study including patients with PI-IBS and intestinal hyperpermeability, L-glutamine (5 g three times a day) led to a significant reduction in all important IBS-related endpoints [79]. While flu-like symptoms continued to be felt for about 1 week every 6 months, general fatigue subsided along with abdominal pain, brain fog, dizziness, poor memory, and extreme tiredness. Bloating, headache, temperature dysregulation, tinnitus, and insomnia had clearly lessened. Diarrhea and bloating occasionally occurred after acute stress or physical exertion, but to a much lesser extent. Arthralgia had almost completely disappeared after a total period of 3 years, even without drug therapy with anti-inflammatory painkillers. Low ambient temperatures and physical exertion no longer necessarily led to the development of flu-like symptoms with the described accompanying complaints. The CDAI score [32] was 87 points in June 2024 (weight 81 kg, hematocrit 43.7%), compared with 183 points at the time of our first intervention.
From the patient’s perspective, there was a life before the diagnosis in February 1981 at the age of 23, and another life afterwards. This sentiment was echoed by the surgical ward physician 6 weeks after ileocecal resection, when the patient was discharged on elemental feed, with persistent diarrhea and 15 kg underweight. The physician said, “Say goodbye to your previous life. Stop studying, sit on a deckchair in the garden, and apply for early retirement. Expect further surgeries every two years as long as you still have intestines.” At that time, the patient felt that Crohn’s disease was something new and rare, and that the treating physicians did not really know how to handle his condition. Medical care seemed more focused on healing the extensive scars extending downwards from below the costal arches: one on the right side from iliopsoas abscess drainage, and the other in the center from the ileocecal resection.
After rehabilitation, he decided to rebuild his body by taking up karate. A few years later, he obtained a PhD in chemistry and worked in demanding academic positions with 12-hour days. He is grateful that his life turned out the way it did, despite the unfavorable prognosis at the time and the many challenging days and weeks along the way.
Yet, over the past four decades, diarrhea has been with him like a faithful companion, although CD was repeatedly diagnosed as being in remission. This raised questions and necessitated meticulous planning and coordination of all work processes, meetings, presentations, and other work-related activities, medical appointments, recreational activities, social engagements, and holidays. The morning hours until 10 a.m. were particularly challenging, as urgent bowel movements were common, even without diarrhea. During this time, however, he was required to lead team meetings for ongoing research programmes. Additionally, throughout the 1990s, his role as a quality manager at a food testing facility with 220 employees demanded constant availability. A particular challenge emerged in 2006 when he assumed management of a research unit at a European Reference Laboratory. Throughout his career, only his closest laboratory assistants were privy to his health issues.
During medical consultations following regular colonoscopies at various hospitals, he received no explanation for his persistent diarrhea. Responses such as “that shouldn't really be happening” or “we still know too little about this rare condition” were perceived as unsympathetic, inadequate, and disappointing, leaving him with a sense of abandonment. Therefore, he wished for more robust medical intervention but was left to manage alone. He explored virtually every option that presented itself, even turning to expensive “healers” twice in vain. He thought food utilization was inadequate or several small portions taken throughout the day as recommended did not last. Nevertheless, he had to maintain peak mental performance for his demanding research leadership role.
Between 2012 and 2016, escalating envy-driven bullying compounded the challenges of his working life. As the symptoms increased in number and worsened in early 2017, the carefully maintained façade began to disintegrate. Peculiarly, he now seemed to contract the flu bimonthly, enduring 2–3 weeks of diarrhea, abdominal pain, and an unprecedented level of fatigue. Resorting to a restricted diet of oatmeal, potatoes, and select vegetables, he attempted to minimize appointments. Had the constant stress further exacerbated the strain on his compromised intestines? Like the proverbial frog in boiling water, had he been oblivious to the gradually worsening conditions? After all these years, was he finally confronting a relapse of Crohn’s disease? As bullying intensified and symptoms deteriorated, he was ultimately compelled to take sick leave in July 2017.
His condition took another massive turn for the worse in March 2019 after a severe 3-week bout of infectious gastroenteritis. The following 3 years were marked by spending two-thirds of his life either in bed or at rest. Exposure to low temperatures, such as during a walk or bike ride, or engaging in physical exercise, would trigger debilitating episodes lasting 2–3 weeks. These phases were marked by a sense of malaise, cold extremities, diarrhea up to four times a day with bloating and abdominal pain, profound fatigue, extreme tiredness, and headaches preceding bowel movements. Additionally, he experienced cognitive difficulties, including impaired focus and word recall. His daily functional window was reduced to a mere 1–2 hours in the late morning, during which he could manage housework or nearby shopping, but these activities would leave him exhausted for the remainder of the day. Returning to work was unthinkable, and all social contacts had ceased. Then, in November 2020, severe hip pain developed, first unilaterally and later bilaterally. By September 2021, after weeks of struggling to walk and contemplating hip replacement, a specialist reviewed his X-rays and MRI scans, diagnosing mild hip osteoarthritis consistent with his age but unable to account for the severity of his pain. Further consultations with specialists in gastroenterology, internal medicine, nutrition, and even psychosomatics (as he felt stress aggravated many of his symptoms) yielded no conclusive explanation for his symptom pattern. Now in early retirement, barely able to eat, walk, or sleep properly, and incapable of engaging in any activities, he felt hopeless, with no light at the end of the tunnel.
Utterly disheartened but persistently encouraged by his wife, a physician at the same university hospital, he resolved to consult a specialist in internal medicine, gastroenterology, and naturopathy at the Centre for Complementary Medicine at the University of Freiburg’s Faculty of Medicine in February 2022, as a last resort. Remarkably, the half-hour consultation was phenomenal and completely turned the tide. In an atmosphere of mutual partnership, empathy, and understanding, he received, for the first time in four decades, a plausible explanation for his persistent diarrhea and the numerous other more recent symptoms. The immense relief and calming, positive effect of finally being so well informed after a long and arduous journey cannot be overstated. Suddenly, his condition and symptoms made perfect sense. He could scarcely have envisaged that his health issues did not stem from remitted Crohn’s disease and recurring flu-like episodes due to a compromised immune system, as previously suggested by some specialists. Instead, he discovered that, in addition to Crohn’s disease, he had developed diarrhea-predominant irritable bowel syndrome, exacerbated by the severe gastrointestinal infection in spring 2019, to which a chronic fatigue syndrome then became associated. He learned that his flu-like symptoms could be reinterpreted as consequences of vegetative nervous system dysfunction, brought on by chronic life stress. This new understanding provided invaluable insight into the origins and interrelations of his symptoms. Nevertheless, during that 30-minute patient-centered consultation, he could not have anticipated the remarkable success of the proposed interventions that would soon follow.
Replacing loperamide with opium tincture, having an early dinner, and managing his physical activities led to an immediate and substantial improvement in his quality of life within just a few days. Diarrhea episodes reduced dramatically from up to four times a day to only once or twice a day on just two to three days a month. The frequency and intensity of bloating, abdominal pain, headache, brain fog, dizziness, impaired memory, extreme tiredness, and insomnia also significantly decreased over the following months, although strong bilateral hip joint pain persisted. For the first time in 5 years, he was able to undertake long-distance flights to North America and visit family and friends in the Asia–Pacific region.
L-glutamine further enhanced and stabilized his condition. Within 4–6 weeks, general fatigue, brain fog, dizziness, impaired memory, and extreme tiredness had largely dissipated. Bloating still occurred occasionally after acute stress or physical exertion but was mild and mostly pain-free. With few exceptions, his sleep duration normalized to 6–7 hours. His diet expanded to include, for the first time in 43 years, wholegrain bread, hard cheese, and French fries. He tolerated up to 90 minutes at an ice rink without subsequent flu-like or gastrointestinal symptoms, and similarly fared well after an intercontinental flight. However, reducing his daily intake of L-glutamine from 20 to 10 g on a trial basis resulted in bloating and general discomfort, which resolved within a few days upon resuming the 20 g dose. Currently, even without painkillers, he experiences only minor and diminishing one-sided hip joint pain. Instead of dressing excessively warm to prevent shivering, as had been necessary even on warm summer days for the past 5 years, he now enjoys wearing T-shirts again in temperatures above 20 °C. He feels more resilient and is able to work intensively for 8 hours a day without gastrointestinal complaints. Coming to terms with his medical history has brought a deep sense of relief and optimism for the future. In essence, thanks to a skilled complementary medicine intervention and comprehensive education, he finally feels liberated from the passive “victim role” and has regained his life.
Discussion and conclusion
Our case presentation illustrates several key aspects. Firstly, it shows that functional diseases (IBS) may occur simultaneously with severe organic diseases (IBD) and that differentiation can be challenging and may be overlooked. Gastroenterologists may have overly focused on endoscopy, while psychosomatic specialists might have been uncertain about their ability to assist this patient. Secondly, it exemplary shows the bidirectional interrelation between IBS, CFS, and fibromyalgia/somatoform pain syndrome. The organic disease (IBD) and IBS presented first, then CFS occurred during a period of massive psychological stress, with the pain syndrome subsequently settling on top. Resolution of symptoms occurred in the same order: IBS improved first, followed by CFS, and finally, the pain disappeared. It is known that the combination of IBS, CFS, and fibromyalgia/chronic pain syndrome is interlinked and indicative of a more severe course than any of these conditions alone [80]. Not all fibromyalgia criteria were met (only hip pain and fatigue), but in the absence of explanatory organic findings, the hip pain can most likely be interpreted as a somatoform symptom. Thirdly, the case report demonstrates the importance of understanding and explaining the patient’s symptoms, even though some, such as deterioration after exposure to cold air, are unusual. An in-depth history-taking, the uncovering of traumatic life experiences since early childhood, and knowledge of autonomic nervous system regulation, temperature regulation, and psycho-neuro-immunological connections proved instrumental in explaining these symptoms. The German S3 Guideline on Irritable Bowel Syndrome [81] emphasizes the importance of properly explaining the nature of functional connections such as the gut–brain axis. However, the expertise of how to explain these connections is beyond the guideline and, to our knowledge, is not an integrative part of the curriculum for medical students, at least in Germany. Furthermore, this case illustrates that a transparent, comprehensible explanation of symptoms, combined with effective symptom management, can lead to rapid and sustained improvement even in a severe, longstanding case of IBS lasting decades and CFS persisting for 3 years. While self-management strategies (such as paced physical training, relaxation techniques, structured daily routines, and dietary adjustments) were beneficial and are recommended in treatment guidelines for IBS [81] and CFS [82,83,84], they alone would not explain the rapid improvement starting already a few days after the initial visit. We assume that physical training and relaxation techniques needed more time to improve our patient’s physical fitness, self-trust, and autonomic regulation. Further important factors contributing to the favorable outcome included, in our view, the patient’s excellent motivation, intellectual capacity to understand the explanations, proactive coping strategies, and trust in both the attending specialist and the treatment process.
Availability of data and materials
Not applicable.
Abbreviations
- AUC:
-
Area under the curve
- BM:
-
Bowel movement
- BRS:
-
Baroreceptor sensitivity
- C6G:
-
Codeine-6-glucuronide
- CD:
-
Crohn’s disease
- CDAI:
-
Crohn’s Disease Activity Index
- CFS:
-
Chronic fatigue syndrome
- CFU:
-
Colony-forming unit
- CNS:
-
Central nervous system
- CRP:
-
C-reactive protein
- DGBI:
-
Disorder of gut–brain interaction
- ENS:
-
Enteric nervous system
- ESR:
-
Erythrocyte sedimentation rate
- FM:
-
Fibromyalgia
- GMC:
-
General medical condition
- HPA:
-
Hypothalamic–pituitary–adrenal
- HR:
-
Heart rate
- IBD:
-
Inflammatory bowel disease
- IBS:
-
Irritable bowel syndrome
- IBS-D:
-
Irritable bowel syndrome with predominant diarrhea
- ICR:
-
Ileocecal resection
- M3G:
-
Morphine-3-glucuronide
- M6G:
-
Morphine-6-glucuronide
- MGB:
-
Microbiota–gut–brain
- MRI:
-
Magnetic resonance imaging
- OGD:
-
Esophagogastroduodenoscopy
- PI-IBS:
-
Post-infectious irritable bowel syndrome
- PNS:
-
Parasympathetic nervous system
- U/S:
-
Ultrasound imaging (sonography)
- UC:
-
Ulcerative colitis
- UZN:
-
Uni-Zentrum Naturheilkunde (University Center for Complementary Medicine)
References
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78. https://doiorg.publicaciones.saludcastillayleon.es/10.1056/NEJMra0804647.
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853):1590–605. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/S0140-6736(12)60026-9.
Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med. 2021;21(2):135–9. https://doiorg.publicaciones.saludcastillayleon.es/10.7861/clinmed.2021-0080.
Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–22. https://doiorg.publicaciones.saludcastillayleon.es/10.2512/jml-2018-0075.
Kamp K, Dudley-Brown S, Heitkemper M, Wyatt G, Given B. Symptoms among emerging adults with inflammatory bowel disease: a descriptive study. Res Nurs Health. 2020;43(1):48–55. https://doiorg.publicaciones.saludcastillayleon.es/10.1002/nur.21985.
Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25(1):46–52. https://doiorg.publicaciones.saludcastillayleon.es/10.1055/s-0032-1301759.
Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759–73. https://doiorg.publicaciones.saludcastillayleon.es/10.3748/wjg.v20.i22.6759.
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simrén M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;24(2):16014. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/nrdp.2016.14.
Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473–86. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/s41575-020-0286-8.
Shrestha B, Patel D, Shah H, Hanna KS, Kaur H, Alazzeh MS, Thandavaram A, Channar A, Purohit A, Venugopal S. The role of gut-microbiota in the pathophysiology and therapy of irritable bowel syndrome: a systematic review. Cureus. 2022;14(8):e28064. https://doiorg.publicaciones.saludcastillayleon.es/10.7759/cureus.28064.
Card T, Enck P, Barbara G, Boeckxstaens GE, Santos J, Azpiroz F, Mearin F, Aziz Q, Marshall J, Spiller R. Post-infectious IBS: defining its clinical features and prognosis using an internet-based survey. United Eur Gastroenterol J. 2018;6(8):1245–53. https://doiorg.publicaciones.saludcastillayleon.es/10.1177/2050640618779923.
Ancona A, Petito C, Iavarone I, Petito V, Galasso L, Leonetti A, Turchini L, Belella D, Ferrarrese D, Addolorato G, Armuzzi A, Gasbarrini A, Scaldaferri F. The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease. Dig Liver Dis. 2021;53(3):298–305. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.dld.2020.11.026.
Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol. 2019;4(8):632–42. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/S2468-1253(19)30089-5.
Günther C, Rothhammer V, Karow M, Neurath M, Winner B. The gut-brain axis in inflammatory bowel disease—current and future perspectives. Int J Mol Sci. 2021;22(16):8870. https://doiorg.publicaciones.saludcastillayleon.es/10.3390/ijms22168870.
Hillestad EMR, van der Meeren A, Nagaraja BH, Bjørsvik BR, Haleem N, Benitez-Paez A, Sanz Y, Hausken T, Lied GA, Lundervold A, Berentsen B. Gut bless you: the microbiota-gut-brain axis in irritable bowel syndrome. World J Gastroenterol. 2022;28(4):412–31. https://doiorg.publicaciones.saludcastillayleon.es/10.3748/wjg.v28.i4.412.
Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes. 2016;7(5):365–83. https://doiorg.publicaciones.saludcastillayleon.es/10.1080/19490976.2016.1218585.
Szałwińska P, Włodarczyk J, Spinelli A, Fichna J, Włodarczyk M. IBS-symptoms in IBD patients-manifestation of concomitant or different entities. J Clin Med. 2020;10(1):31. https://doiorg.publicaciones.saludcastillayleon.es/10.3390/jcm10010031.
Fu Y, Waghray N, Fass R, Song G. Diagnostic implications of irritable bowel syndrome is an independent risk factor for undergoing surgical interventions in patients with inflammatory bowel disease. Diagnostics. 2023;13(11):1901. https://doiorg.publicaciones.saludcastillayleon.es/10.3390/diagnostics13111901.
Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97(2):389–96. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/j.1572-0241.2002.05475.x.
Ozer M, Bengi G, Colak R, Cengiz O, Akpinar H. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life. Medicine. 2020;99(19):e20067. https://doiorg.publicaciones.saludcastillayleon.es/10.1097/MD.0000000000020067.
Abdul Rani R, Raja Ali RA, Lee YY. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res. 2016;14(4):297–304. https://doiorg.publicaciones.saludcastillayleon.es/10.5217/ir.2016.14.4.297.
Sezgin O, Boztepe B, Üçbilek E, Altintas E, Celikcan HD. Irritable bowel syndrome on inflammatory bowel disease in deep remission: no relation with remission deepening and inflammation. Turk J Gastroenterol. 2021;32(10):870–8. https://doiorg.publicaciones.saludcastillayleon.es/10.5152/tjg.2021.20806.
Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology. 2017;153(3):723-731.e1. https://doiorg.publicaciones.saludcastillayleon.es/10.1053/j.gastro.2017.05.056.
Huisman D, Sweeney L, Bannister K, Moss-Morris R. Irritable bowel syndrome in inflammatory bowel disease: distinct, intertwined, or unhelpful? Views and experiences of patients. Cogent Psychol. 2022;9(1):1–19. https://doiorg.publicaciones.saludcastillayleon.es/10.1080/23311908.2022.2050063.
Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053–62. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/S2468-1253(20)30300-9.
Street RL Jr, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns. 2009;74(3):295–301. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.pec.2008.11.015.
Paterick TE, Patel N, Tajik AJ, Chandrasekaran K. Improving health outcomes through patient education and partnerships with patients. Proc. 2017;30(1):112–3. https://doiorg.publicaciones.saludcastillayleon.es/10.1080/08998280.2017.11929552.
Kadji K, Schmid MM. The effect of physician self-disclosure on patient self-disclosure and patient perceptions of the physician. Patient Educ Couns. 2021;104(9):2224–31. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.pec.2021.02.030.
Correia JC, Waqas A, Assal JP, Davies MJ, Somers F, Golay A, Pataky Z. Effectiveness of therapeutic patient education interventions for chronic diseases: a systematic review and meta-analyses of randomized controlled trials. Front Med. 2023;25(9):996528. https://doiorg.publicaciones.saludcastillayleon.es/10.3389/fmed.2022.996528.
Cross E, Prior JA, Farmer AD, Saunders B. Patients’ views and experiences of delayed diagnosis of inflammatory bowel disease: a qualitative study. BJGP Open. 2023. https://doiorg.publicaciones.saludcastillayleon.es/10.3399/BJGPO.2023.0070.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–53. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gut.2005.082909.
Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index (CDAI). Gastroenterology. 1979;77(4 Pt 2):843–6.
Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simrén M, Spiller R. Bowel disorders. Gastroenterology. 2016. https://doiorg.publicaciones.saludcastillayleon.es/10.1053/j.gastro.2016.02.031.
Lowman BC, Drossman DA, Cramer EM, McKee DC. Recollection of childhood events in adults with irritable bowel syndrome. J Clin Gastroenterol. 1987;9(3):324–30. https://doiorg.publicaciones.saludcastillayleon.es/10.1097/00004836-198706000-00017.
Chitkara DK, van Tilburg MA, Blois-Martin N, Whitehead WE. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol. 2008;103(3):765–74. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/j.1572-0241.2007.01722.x.
Low EXS, Mandhari MNKA, Herndon CC, Loo EXL, Tham EH, Siah KTH. Parental, perinatal, and childhood risk factors for development of irritable bowel syndrome: a systematic review. J Neurogastroenterol Motil. 2020;26(4):437–46. https://doiorg.publicaciones.saludcastillayleon.es/10.5056/jnm20109.
Bradford K, Shih W, Videlock EJ, Presson AP, Naliboff BD, Mayer EA, Chang L. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol. 2012;10(4):385–90. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.cgh.2011.12.018.
Chandan JS, Keerthy D, Zemedikun DT, Okoth K, Gokhale KM, Raza K, Bandyopadhyay S, Taylor J, Nirantharakumar K. The association between exposure to childhood maltreatment and the subsequent development of functional somatic and visceral pain syndromes. EClinicalMedicine. 2020;6(23):100392. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.eclinm.2020.100392.
Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(2):131–9. https://doiorg.publicaciones.saludcastillayleon.es/10.5056/jnm.2011.17.2.131.
Agrawal M, Sabino J, Frias-Gomes C, Hillenbrand CM, Soudant C, Axelrad JE, Shah SC, Ribeiro-Mourão F, Lambin T, Peter I, Colombel JF, Narula N, Torres J. Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses. EClinicalMedicine. 2021;15(36):100884. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.eclinm.2021.100884.
Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20(39):14126–31. https://doiorg.publicaciones.saludcastillayleon.es/10.3748/wjg.v20.i39.14126.
Sapra A, Bhandari P. Chronic fatigue syndrome. Treasure Island: StatPearls Publishing; 2024.
Schneider KM, Blank N, Alvarez Y, Thum K, Lundgren P, Litichevskiy L, Sleeman M, Bahnsen K, Kim J, Kardo S, Patel S, Dohnalová L, Uhr GT, Descamps HC, Kircher S, McSween AM, Ardabili AR, Nemec KM, Jimenez MT, Glotfelty LG, Eisenberg JD, Furth EE, Henao-Mejia J, Bennett FC, Pierik MJ, Romberg-Camps M, Mujagic Z, Prinz M, Schneider CV, Wherry EJ, Bewtra M, Heuckeroth RO, Levy M, Thaiss CA. The enteric nervous system relays psychological stress to intestinal inflammation. Cell. 2023;186(13):2823–38. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.cell.2023.05.001.
Friesen HJ, Thompson P, Schurman JV, Colombo JM, Friesen CA. Overactive bladder syndrome symptoms in youth with abdominal pain-associated disorders of gut-brain interaction. Sci Rep. 2023;13(1):11042. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/s41598-023-37937-w.
Piętak PA, Rechberger T. Overactive bladder as a dysfunction of the autonomic nervous system—a narrative review. Eur J Obstet Gynecol Reprod Biol. 2022;271:102–7. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.ejogrb.2022.01.022.
Szymusiak R. Body temperature and sleep. Handb Clin Neurol. 2018;156:341–51. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/B978-0-444-63912-7.00020-5.
Benarroch EE. Physiology and pathophysiology of the autonomic nervous system. Continuum. 2020;26(1):12–24. https://doiorg.publicaciones.saludcastillayleon.es/10.1212/CON.0000000000000817.
Pérgola PE, Kellogg DL Jr, Johnson JM, Kosiba WA, Solomon DE. Role of sympathetic nerves in the vascular effects of local temperature in human forearm skin. Am J Physiol. 1993;265(3 Pt 2):H785–92. https://doiorg.publicaciones.saludcastillayleon.es/10.1152/ajpheart.1993.265.3.H785.
Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome. Mayo Clin Proc. 2023;98(10):1544–51. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.mayocp.2023.07.032.
Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab. 2010;12(7):79. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/1743-7075-7-79.
Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. 2018;67(6):1078–86. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gutjnl-2017-313713.
Monden R, Rosmalen JGM, Wardenaar KJ, Creed F. Predictors of new onsets of irritable bowel syndrome, chronic fatigue syndrome and fibromyalgia: the lifelines study. Psychol Med. 2022;52(1):112–20. https://doiorg.publicaciones.saludcastillayleon.es/10.1017/S0033291720001774.
El-Salhy M. Intestinal bacteria associated with irritable bowel syndrome and chronic fatigue. Neurogastroenterol Motil. 2023;35(9):e14621. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/nmo.14621.
Jerem P, Romero LM. It’s cool to be stressed: body surface temperatures track sympathetic nervous system activation during acute stress. J Exp Biol. 2023;226(20):jeb246552. https://doiorg.publicaciones.saludcastillayleon.es/10.1242/jeb.246552.
Zhou Q, Fillingim RB, Riley JL 3rd, Verne GN. Thermal hypersensitivity in a subset of irritable bowel syndrome patients. World J Gastroenterol. 2009;15(26):3254–60. https://doiorg.publicaciones.saludcastillayleon.es/10.3748/wjg.15.3254.
Zhou Q, Verne GN. New insights into visceral hypersensitivity–clinical implications in IBS. Nat Rev Gastroenterol Hepatol. 2011;8(6):349–55. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/nrgastro.2011.83.
Zuo XL, Li YQ, Shi L, Lv GP, Kuang RG, Lu XF, Li JM, Desmond PV. Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome. J Gastroenterol. 2006;41(4):311–7. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s00535-005-1766-x.
Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology. 2003;124(6):1662–71. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/s0016-5085(03)00324-x.
Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535–44. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/j.1365-2036.2007.03399.x.
Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut. 2002;51(3):410–3. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gut.51.3.410.
Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–11. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gut.47.6.804.
Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol. 2007;42(Suppl 17):41–7. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s00535-006-1925-8.
Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009;15(29):3591–6. https://doiorg.publicaciones.saludcastillayleon.es/10.3748/wjg.15.3591.
Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605–11. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gut.2009.202234.
Berumen A, Lennon R, Breen-Lyles M, Griffith J, Patel R, Boxrud D, Decuir M, Farrugia G, Smith K, Grover M. Characteristics and risk factors of post-infection irritable bowel syndrome after campylobacter enteritis. Clin Gastroenterol Hepatol. 2021;19(9):1855–63. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.cgh.2020.07.033.
Schiller LR. Antidiarrheal drug therapy. Curr Gastroenterol Rep. 2017;19(5):18. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s11894-017-0557-x.
Jehle EC. High-output-stoma. Coloproctology. 2019;41:344–8. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s00053-019-00396-x.
Okdahl T, Mark EB, Nedergaard RB, Knoph CS, Cook ME, Krogh K, Drewes AM. Effects of opium tincture on the enteric and central nervous systems: a randomized controlled trial. Basic Clin Pharmacol Toxicol. 2023;132(5):434–48. https://doiorg.publicaciones.saludcastillayleon.es/10.1111/bcpt.13850.
Dahlgren D, Hellström PM. Medicinal grade opium tincture for severe diarrhea: effect revisited in observational study. Curr Opin Gastroenterol. 2024;40(3):196–202. https://doiorg.publicaciones.saludcastillayleon.es/10.1097/MOG.0000000000000985.
Dittbrenner A, Mock A-P, Börner A, Lohwasser U. Variability of alkaloid content in Papaver somniferum L. J Appl Bot Food Qual. 2009;82:103–7.
Hoskin PJ, Hanks GW. Morphine: pharmacokinetics and clinical practice. Br J Cancer. 1990;62(5):705–7. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/bjc.1990.363.
Lötsch J, Weiss M, Ahne G, Kobal G, Geisslinger G. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology. 1999;90(4):1026–38. https://doiorg.publicaciones.saludcastillayleon.es/10.1097/00000542-199904000-00016.
Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990;47(1):12–9. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/clpt.1990.2.
Chan L-N, DiBaise JK, Parrish CR. Short Bowel Syndrome in Adults – Part 4B A Guide to Front Line Drugs Used in the Treatment of Short Bowel Syndrome. Pract Gastroenterol. 2015 Apr;XXXIX:32–38.
Kasper S, Volz HP, Dienel A, Schläfke S. Efficacy of Silexan in mixed anxiety-depression–a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2016;26(2):331–40. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.euroneuro.2015.12.002.
Kasper S, Anghelescu I, Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep–a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(11):1960–7. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.euroneuro.2015.07.024.
Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17(2):94–9. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.phymed.2009.10.006.
Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut. 2010;59(6):775–84. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gut.2009.181834.
Zhou Q, Verne ML, Fields JZ, Lefante JJ, Basra S, Salameh H, Verne GN. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996–1002. https://doiorg.publicaciones.saludcastillayleon.es/10.1136/gutjnl-2017-315136.
van der Meulen ML, Bos M, Bakker SJL, Gans ROB, Rosmalen JGM. Validity and diagnostic overlap of functional somatic syndrome diagnoses. J Psychosom Res. 2024;181:111673. https://doiorg.publicaciones.saludcastillayleon.es/10.1016/j.jpsychores.2024.111673.
Layer P, Andresen V, Allescher H, et al. Update S3-leitlinie reizdarmsyndrom: definition, pathophysiologie, diagnostik und therapie. gemeinsame leitlinie der deutschen gesellschaft für gastroenterologie, verdauungs- und stoffwechselkrankheiten (DGVS) und der deutschen gesellschaft für neurogastroenterologie und motilität (DGNM)–Juni 2021–AWMF-registriernummer: 021/016. Z Gastroenterol. 2021;59(12):1323–415. https://doiorg.publicaciones.saludcastillayleon.es/10.1055/a-1591-4794.
Baum E, Lindner N, Andreas S et al. S3 Leitlinie Müdigkeit der Deutschen Gesellschaft für Allgemeinmedizin – Dezember 2022 – AWMF register number 053–002. Weblink. https://register.awmf.org/assets/guidelines/053-002l_S3_Muedigkeit_2023-01_01.pdf. Accessed on August 20th, 2024.
Baum E, Lindner N, Maisel P. German S3 Guideline Fatigue/Tiredness English short version – December 2022 – AWMF register number 053–002ke. Weblink. https://register.awmf.org/assets/guidelines/053_D_Ges_fuer_Allgemeinmedizin_und_Familienmedizin/053-002ke_S3_Fatigue-Tiredness_2023-05.pdf. Accessed on August 20th, 2024.
Kornder N, Baum E, Maisel P, Lindner N. Müdigkeit–update der S3-leitlinie [Tiredness/Fatigue-S3 guideline update]. ZFA. 2023;99(3):127–32. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s44266-023-00045-z.
Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313(11):1101–2. https://doiorg.publicaciones.saludcastillayleon.es/10.1001/jama.2015.1346.
van der Veek PP, Swenne CA, Hv V, Schoneveld AL, Maestri R, Masclee AA. Viscerosensory-cardiovascular reflexes: altered baroreflex sensitivity in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol. 2005;289(4):970–6. https://doiorg.publicaciones.saludcastillayleon.es/10.1152/ajpregu.00607.2004.
Acknowledgements
None.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
RH evaluated the patient’s medical history, provided diagnostical interpretation, therapeutic approach, and conceptual design of this case report. RH contributed the “Discussion and conclusion” section, prepared the final manuscript and supervised the project. JH drafted the “Background” and “Case presentation” sections, acquired patient data, and contributed Tables 1 and 2. Both authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Competing interests
The authors have no competing interests relevant to this article.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Haedrich, J., Huber, R. Crohn’s disease, irritable bowel syndrome, and chronic fatigue: the importance of communication and symptom management—a case report. J Med Case Reports 19, 9 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13256-024-05010-3
Received:
Accepted:
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13256-024-05010-3